{"id":251395,"date":"2021-11-01T00:00:00","date_gmt":"2021-11-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidop0030-biopharma-achromatopsia-epidemiology-mature-markets-data\/"},"modified":"2026-03-31T10:42:05","modified_gmt":"2026-03-31T10:42:05","slug":"epidop0030-biopharma-achromatopsia-epidemiology-mature-markets-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0030-biopharma-achromatopsia-epidemiology-mature-markets-data\/","title":{"rendered":"Achromatopsia &#8211; Epidemiology &#8211; Mature Markets Data"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of achromatopsia (<abbr title=\"achromatopsia\">ACHM<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr title=\"achromatopsia\">ACHM<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"achromatopsia\">ACHM<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"achromatopsia\">ACHM<\/abbr>, how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"achromatopsia\">ACHM<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"multiple sclerosis\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts four <abbr title=\"achromatopsia\">ACHM<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr title=\"achromatopsia\">ACHM<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"10311\" title=\"achromatopsia\">ACHM<\/abbr> by CNGA3+ mutation.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"achromatopsia\">ACHM<\/abbr> by CNGB3+ mutation.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"achromatopsia\">ACHM<\/abbr> by other\/unknown status.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251395","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ophthalmology","biopharma-product-epidemiology","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251395\/revisions"}],"predecessor-version":[{"id":283830,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251395\/revisions\/283830"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}